de Duve Institute
Desconocido
INCITE: Immune Niches for Cancer ImmunoTherapy Enhancement
DE DUVE INSTITUTE AISBL
participó en un
H2020:
H2020-FETOPEN-2018-2020
Cancer is rapidly becoming the most frequent cause of morbidity and mortality in the EU, accounting for a quarter of all deaths in EU. Witho...
2020-12-21 - 2025-04-30 | Financiado
2020-12-21 - 2025-04-30 | Financiado
TheraLymph: Gene Therapy to restore lymphatic flow lymphedema
DE DUVE INSTITUTE AISBL
participó en un
H2020:
H2020-SC1-BHC-2018-2020
Lymphedema is a disabling condition induced by the accumulation of fluid and fat in the arm or in the leg. It is an untreatable disease that...
2019-11-24 - 2025-06-30 | Financiado
2019-11-24 - 2025-06-30 | Financiado
IMMUcan: Integrated IMMUnoprofiling of large adaptive CANcer patients cohorts
DE DUVE INSTITUTE AISBL
participó en un
H2020:
H2020-JTI-IMI2-2017-13-two-stage
IMMUcan proposes an inclusive and integrated European immuno-oncology platform. IMMUcan will access high-quality human biological material...
2019-04-23 - 2025-08-31 | Financiado
2019-04-23 - 2025-08-31 | Financiado
V.A. Cure: A multidisciplinary approach towards sustainable improvement in rare diseases care uniting Europe s...
DE DUVE INSTITUTE AISBL
tramitó un
H2020:
H2020-MSCA-ITN-2018
Vascular anomalies (VAs) is a group of rare diseases defined by blood- or lymph vessel dysfunction causing chronic pain, disabilities, and e...
2018-09-13 - 2023-02-28 | Financiado
2018-09-13 - 2023-02-28 | Financiado
Pan3DP: 3D bioprinting of pancreatic tissue for biomedical research
DE DUVE INSTITUTE AISBL
participó en un
H2020:
H2020-FETOPEN-2016-2017
Developing therapies for pancreatic diseases, such as diabetes and pancreatic cancer, is hampered by a limited access to pancreatic tissue i...
2018-05-03 - 2022-09-30 | Financiado
2018-05-03 - 2022-09-30 | Financiado
MESI-STRAT: Systems Medicine of Metabolic Signaling Networks A New Concept for Breast Cancer Patient Stratifica...
DE DUVE INSTITUTE AISBL
participó en un
H2020:
H2020-SC1-2016-2017
Breast cancer (BC) is a complex disease with high prevalence in the EU. 75% of the tumors are estrogen receptor-positive (ER+), and are trea...
2017-11-21 - 2023-09-30 | Financiado
2017-11-21 - 2023-09-30 | Financiado
PIMT and signaling: Interaction between the protein repair enzyme L isoaspartyl methyltransferase and insulin IGF 1 sign...
DE DUVE INSTITUTE AISBL
participó en un
FP7:
The protein L-isoaspartyl methyltransferase (PIMT) is well known for its protein repair function, namely the reconversion of deamidated and/...
Financiado
Financiado
BOLD: Biology of Liver and Pancreatic Development and Disease
DE DUVE INSTITUTE AISBL
participó en un
FP7:
Aims: provide a cutting edge research training programme encompassing complementary approaches to the investigation of liver and pancreatic...
Financiado
Financiado
* No se disponen de datos de la empresa actual.